PT-141
★ 78 FDA approvedBremelanotide (Vyleesi)
Sexual desire for both women and men
Sexual HealthAbout
A melanocortin receptor agonist that acts on the brain to increase sexual desire — not the vascular system (unlike Viagra). FDA approved 2019.
Mechanism
Activates MC3R and MC4R receptors in the dopamine pathways of the brain that govern libido and arousal.
Dosage
beginner
- Amount
- 500-750 mcg
- Frequency
- On-demand, 45 min before activity
- Route
- SubQ
- Duration
- On-demand
standard
- Amount
- 1.0-1.75 mg
- Frequency
- On-demand, max 8x per month
- Route
- SubQ
- Duration
- On-demand
advanced
- Amount
- 1.75 mg
- Frequency
- On-demand, max 8 doses/month
- Route
- SubQ
- Duration
- On-demand
45 min - 4 hours before sex. Not on an empty stomach (worst nausea).
On-demand. Not daily.
Reconstitution & Storage
Store refrigerated after reconstitution.
Dosing reference — units to draw
Concentration = peptide mass ÷ bacteriostatic water; units to draw = dose volume (mL) × 100 on a U-100 insulin syringe. Each vial size below is shown at 1 mL, with the units to draw for a typical 500–1000 mcg dose.
| Vial | BAC water | Concentration | Units to draw |
|---|---|---|---|
| 5 mg | 1 mL | 5000 mcg/mL | 10–20 units |
| 10 mg | 1 mL | 10000 mcg/mL | 5–10 units |
Lyophilized: cool. Reconstituted: 2-8°C, 4 weeks.
Benefits
- • Increases sexual desire (both sexes)
- • Helps with ED when PDE5 inhibitors do not work
- • Acts on the brain, not the vasculature
- • No need for visual stimulation
Side effects
- • Nausea (very common, 40%+)
- • Facial flushing
- • Transient blood pressure increase
- • Headache
- • Skin darkening with repeated use (rare)
Contraindications
- • Hypertension (uncontrolled)
- • Cardiovascular disease
- • Pregnancy
Gender notes
Men
Off-label use. 1-1.75 mg common. Sometimes stacked with tadalafil.
Women
FDA approved for premenopausal HSDD. 1.75 mg standard. No post-menopausal indication yet.
Research
- RECONNECT studies: Bremelanotide for HSDD ↗
Phase 3 RCT, 1247 women. Significant increase in sexual desire vs placebo.
Obstetrics & Gynecology · 2019
- Rosen RC et al: PT-141 safety and pharmacokinetics ↗
Early study of PT-141 in men with ED.
International Journal of Impotence Research · 2004
Stacks well with
PT-141 FAQ
How do you reconstitute PT-141?
Add 1 mL of bacteriostatic water to a 5 mg vial of PT-141, which gives a concentration of 5000 mcg/mL. Inject the water slowly down the vial wall and swirl gently — never shake.
What is a typical PT-141 dose?
A typical research dose of PT-141 is 500–1000 mcg, on-demand, max 8x per month. This is educational information, not medical advice.
How many units of PT-141 do I draw?
From a 5 mg vial reconstituted with 1 mL of bacteriostatic water, draw 10–20 units on a U-100 insulin syringe for a 500–1000 mcg dose.
Track PT-141 doses in the app
Built-in reconstitution calculator, dose log, and reminders. Free on Android.
Get on Google PlayEducational use only. Not medical advice. Many peptides shown are not FDA-approved and remain research compounds. Always consult a qualified healthcare provider.